Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.45 |
| ▸ | TACR1 | P25103 | 3/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6545522 | 0.98 | KMT2A (0.46) | KMT2APAX8NOS1NOS3TAAR1 | |
| SCHEMBL15211767 | 0.90 | NOS1 (0.53) | KMT2APAX8NOS1NOS3TAAR1 | |
| SCHEMBL13590877 | 0.89 | TAAR1 (0.51) | KMT2APAX8NOS1NOS3TAAR1 | |
| SCHEMBL16516116 | 0.89 | NOS1 (0.46) | KMT2APAX8NOS1NOS3TAAR1 | |
| SCHEMBL15211305 | 0.87 | TAAR1 (0.50) | KMT2APAX8NOS1NOS3TAAR1 | |
| SCHEMBL15211722 | 0.84 | CHRM2 (0.53) | KMT2APAX8NOS1NOS3TAAR1 | |
| SCHEMBL16515747 | 0.84 | KMT2A (0.43) | KMT2APAX8NOS1NOS3TAAR1 | |
| SCHEMBL15211532 | 0.84 | TACR1 (0.42) | KMT2APAX8NOS1NOS3TAAR1 | |
| SCHEMBL3920885 | 0.81 | TAAR1 (0.61) | KMT2APAX8TAAR1IDO1ATM | |
| SCHEMBL20153902 | 0.80 | IDO1 (0.46) | KMT2APAX8NOS1NOS3TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256470-B1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA FARBER CANCER INST INC (US) | 2023-07-26 | — | — | EP | disclosed |
| EP-3036236-A1 | NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS II | LEO PHARMA A/S (DK) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015024878-A1 | NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS II | LEO PHARMA A/S (DK) | 2015-02-26 | — | — | WO | disclosed |
| WO-2015024203-A1 | NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS II | LEO PHARMA A/S (DK) | 2015-02-26 | — | — | WO | disclosed |
| EP-2817312-A1 | NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS | Leo Pharma A/S (DK) | 2014-12-31 | — | — | EP | disclosed |
| WO-2013124286-A1 | NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS | LEO PHARMA A/S (DK) | 2013-08-29 | — | — | WO | disclosed |
| WO-2012175434-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING VESTIPITANT | GLAXO GROUP LIMITED (GB) | 2012-12-27 | — | — | WO | disclosed |
| EP-2170064-A1 | 6.5-PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2010-04-07 | — | — | EP | disclosed |
| US-7625904-B2 | Methods for the treatment of sleep disorders | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1460066-B1 | Piperazine compounds as Tachykinins inhibitors | GLAXO GROUP LTD (GB) | 2009-07-01 | — | — | EP | disclosed |
| US-20020133012-A1 | Process for preparing guanidine and amidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-19 | — | — | US | disclosed |
| US-6429328-B2 | REACTING AN AMIDE DERIVATIVE WITH A PIPERIDINE CONTAINING GUANIDINE GROUP TO PRODUCE THE PRODUCT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-08-06 | — | — | US | disclosed |
| EP-0885204-B1 | NOVEL ARYL GLYCINAMIDE DERIVATIVES, METHOD OF PRODUCING SAID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | BOEHRINGER INGELHEIM PHARMA (DE) | 2002-06-12 | — | — | EP | disclosed |
| US-20020010173-A1 | Processes and intermediate compounds for preparing guanidine and amidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-01-24 | — | — | US | disclosed |
| US-6277840-B1 | ANTIINFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-08-21 | — | — | US | disclosed |
| EP-1086088-A2 | NOVEL NEUROKININ ANTAGONISTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | Boehringer Ingelheim Pharma KG (DE) | 2001-03-28 | — | — | EP | disclosed |
| US-6103719-A | NEUROKININ-A- OR NEUROKININ-B TACHNKININ ANTAGONISTIC PROPERTIES; SUBSTANCE P ANTAGONISM; RESPIRATORY, GASTROINTESTINAL, NERVOUS SYSTEM, SKIN DISORDERS; | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-08-15 | — | — | US | disclosed |
| WO-1999062893-A2 | NOVEL NEUROKININ ANTAGONISTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPOUNDS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-12-09 | — | — | WO | disclosed |
| EP-0885204-A1 | NOVEL ARYL GLYCINAMIDE DERIVATIVES, METHOD OF PRODUCING SAID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | Boehringer Ingelheim Pharma KG (DE) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997032865-A1 | NOVEL ARYL GLYCINAMIDE DERIVATIVES, METHOD OF PRODUCING SAID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010173-A1 | Processes and intermediate compounds for preparing guanidine and amidine derivatives | CCKAR, NPY2R, CCKBR | KMT2A 2199/4885PAX8 2885/4885NOS1 980/4885 |
| US-20020133012-A1 | Process for preparing guanidine and amidine derivatives | NPY2R, NPY1R, CCKAR | KMT2A 1943/4885PAX8 2408/4885NOS1 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.